A detailed history of China Universal Asset Management Co., Ltd. transactions in Immunovant, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 28,151 shares of IMVT stock, worth $774,434. This represents 0.09% of its overall portfolio holdings.

Number of Shares
28,151
Previous 17,160 64.05%
Holding current value
$774,434
Previous $453,000 70.86%
% of portfolio
0.09%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$27.51 - $27.51 $302,362 - $302,362
10,991 Added 64.05%
28,151 $774,000
Q2 2024

Jul 19, 2024

SELL
$25.1 - $31.61 $270,477 - $340,629
-10,776 Reduced 38.57%
17,160 $453,000
Q1 2024

Apr 29, 2024

BUY
$30.27 - $43.79 $339,084 - $490,535
11,202 Added 66.94%
27,936 $903,000
Q4 2023

May 21, 2024

SELL
$31.31 - $44.19 $350,734 - $495,016
-11,202 Reduced 40.1%
16,734 $705,000
Q4 2023

Jan 23, 2024

BUY
$31.31 - $44.19 $418,739 - $590,997
13,374 Added 398.04%
16,734 $705,000
Q3 2023

May 21, 2024

BUY
$18.55 - $39.96 $30,626 - $65,973
1,651 Added 96.61%
3,360 $128,000
Q3 2023

Oct 30, 2023

BUY
$18.55 - $39.96 $30,626 - $65,973
1,651 Added 96.61%
3,360 $129,000
Q2 2023

May 21, 2024

SELL
$14.2 - $23.75 $781 - $1,306
-55 Reduced 3.12%
1,709 $32,000
Q2 2023

Jul 27, 2023

SELL
$14.2 - $23.75 $781 - $1,306
-55 Reduced 3.12%
1,709 $32,000
Q1 2023

May 21, 2024

BUY
$15.27 - $19.72 $6,902 - $8,913
452 Added 34.45%
1,764 $27,000
Q1 2023

Apr 27, 2023

BUY
$15.27 - $19.72 $6,902 - $8,913
452 Added 34.45%
1,764 $27,000
Q4 2022

May 21, 2024

SELL
$6.59 - $17.75 $175,452 - $472,576
-26,624 Reduced 95.3%
1,312 $23,000
Q4 2022

Jan 31, 2023

BUY
$6.59 - $17.75 $1,449 - $3,905
220 Added 20.15%
1,312 $23,000
Q3 2022

Oct 21, 2022

BUY
$3.93 - $6.37 $4,291 - $6,956
1,092 New
1,092 $6,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.